ClinicalTrials.gg
Enrolling by invitationNCT06755515Updated Jan 1, 2025

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

A Phase 2/3 interventional study of Rulonilimab and Placebo in Cervical Cancer, sponsored by Shandong New Time Pharmaceutical Co., LTD. Enrolling by invitation at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-01.

Sponsored by Shandong New Time Pharmaceutical Co., LTD (part of Lunan Pharmaceutical Group) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
59th of 360
510 · median 90
Started
2024
with 60 others
Phase 2/3
11 of 455
6 open now
Primary completion
2028-09
later than 216 of 239 live
Registered
379th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 59th largest by planned enrollment of the 360 interventional ones that give a count, is one of 61 that started in 2024, is one of 11 in phase 2/3, reaches primary completion later than 216 of the 239 other live ones, and was the 379th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.

Read the detailed description

The trial was divided into screening period, treatment period and follow-up period. Participants entered the screening period after signing informed consent and met the inclusion criteria. Subjects who did not meet the exclusion criteria were treated with Rulonilimab/placebo plus chemotherapy ± bevacizumab, intravenously, at target dose every 3 weeks until disease progression or intolerable toxicity or withdrawal for other reasons, for a maximum of 2 years.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 years and above;
  2. Patients with advanced ([FIGO] stage IVB) cervical cancer, patients with persistent, recurrent or cervical cancer that progresses confirmed by histopathology or cytology, and the following conditions must be met:

    Programmed Cell Death Ligand 1 () positive expression defined by Combined Positive Score (CPS) ≥1; The histopathology types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma; Not amenable to curative surgery or concurrent chemoradiotherapy; No prior systemic therapy for advanced, persistent, recurrent or metastatic disease; Patients who had previously received platinum-containing or neoadjuvant chemotherapy/radical concurrent chemoradiotherapy and whose time from the last chemotherapy to disease progression was > 6 months were eligible for inclusion.

  3. According to RECIST1.1 criteria, subjects must have at least one measurable target lesion examined by Imaging tests (including Not to receive radiation therapy or other locoregional therapy unless the lesion PD or has tumor activity by -confirmed);
  4. Those with 0-1 scores on the American Eastern Oncology Collaboration Group () scale
  5. Expected survival ≥3 months;
  6. Those who agree to provide archived tumor tissue samples or before randomized within 3 years or fresh tissue samples;
  7. The function of vital organs meets the following requirements (drugs with blood components and cell growth factors are not allowed to be used within 2 weeks before the first administration) :

    Blood routine: ≥1.5×109/L; ≥75×109/L; ≥90g/L; Liver function: ≤1.5×, and AST≤2.5×ULN; If liver metastasis was present, TBIL≤3×ULN, ALT and AST≤5×ULN; Renal function: serum creatinine (Cr) ≤1.5×ULN a (CrCl) ≥ 50 mL/min if Cr>1.5×ULN; Coagulation function: (INR) ≤1.5×ULN and activated partial thromboplastin time (APTT) ≤1.5×ULN.

    Thyroid function: Thyroid stimulating hormone (TSH) in the normal range; If TSH is abnormal, free triiodothyronine (FT3) and free thyroxine (FT4) must be normal or abnormal without clinical significance.

  8. Willingness to participate in the clinical trial; completely understanding and knowing about the study and signing the ICF; willingness and capability to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with pathological tissue types of mucinous adenocarcinoma, gastric adenocarcinoma, clear cell adenocarcinoma, mesonephric tubular adenocarcinoma and other special types of adenocarcinoma;
  2. Those who previously treated with T-cell co-stimulation, Antiangiogenic drugs (bevacizumab), (anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies), Targeting immune co-stimulatory factors drug (ICOS, 0, CD137, GITR, OX40 antibodies);
  3. Those who have received anti-tumor treatment within 4 weeks before the first dose or within 5 half-lives of the drug (whichever is shorter);
  4. , systemic hormone therapy within 2 weeks prior to initial administration for immunosuppressive purposes (daily dose equivalent to prednisone>10mg of systemic );
  5. The toxicity of previous anti-tumor therapy did not return to V5.0 ≤ grade 1 (except hair loss);
  6. A history of other within the last 5 years, except locally curable cancers (limited to Radical melanoma, basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast);
  7. Patients with primary central nervous system (CNS) malignancies, that have failed local treatment, and carcinomatous meningitis; the following conditions can be included (regular imaging examinations of the disease site): a. No progressive CNS symptoms caused by brain metastases, no need for steroid hormone treatment, and the lesion is less than 1.5 cm; b. Stable for ≥4 weeks after adequate treatment and neurological symptoms (excluding residual signs or symptoms) have returned to baseline levels for >2 weeks before the first dose;
  8. Patients with uncontrollable pleural effusion, pericardial effusion or peritoneal effusion that requires repeated drainage (more than once a month) (can be enrolled after stable treatment for more than 1 month);
  9. Patients with a history of organ transplantation or bone marrow transplantation; or autologous stem cell transplantation within 3 months before the first dose;
  10. Patients who have undergone major surgery or have not yet recovered from surgery within 4 weeks before the first dose (except for diagnostic surgery);
  11. Physical examination or laboratory test findings:

    : HBsAg positive and/or HBcAb positive, and HBV-DNA>500IU/mL or 2500 copies/mL; : HCV antibody positive, and HCV-RNA positive or above the value; antibody (Anti-HIV) positive; Active Treponema pallidum infection;

  12. Patients with thrombosis who need treatment in the acute stage;
  13. Those who have uncontrolled or severe cardiovascular disease, such as (NYHA) Class II or above congestive heart failure or \<50%, unstable angina, myocardial infarction and other cardiovascular disease within 6 months before the first dose; Poorly controlled arrhythmias; Difficult to control hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg after drug therapy);
  14. Patients with the following medical histories, including but not limited to active diseases, active infections (such as active tuberculosis), severe mental illness, severe endocrine diseases (such as type 1 diabetes, type 2 diabetes that cannot be controlled by drugs), etc.;
  15. have been treated with any other drug/device within 4 weeks prior to initial dosing;
  16. Those who have a history of drug abuse or alcoholism within 6 months before the first dose;
  17. Those with a history of severe allergies, known subjects to have been allergic to macromolecular protein preparations/monoclonal antibodies and any components of the experimental drugs;
  18. Those who have received live or attenuated within 4 weeks before the first dose or are scheduled to receive live or attenuated live vaccines during the study;
  19. Pregnant or lactating women, and female subjects of childbearing age who do not agree to use medically recognized effective measures (such as intrauterine devices or condoms) during the study and within 6 months after the last trial drug treatment;
  20. Those who were judged not suitable for inclusion by the researchers.
  21. The following conditions are only applicable to those who are excluded from the use of bevacizumab:

    1. Within 3 months before the first dose, there is hematuria, hematemesis or hemoptysis (>2.5mL red blood), or other history of obvious bleeding (such as pulmonary hemorrhage);
    2. Patients who are receiving thrombolytic/anticoagulant therapy, or need to continue to receive thrombolytic/anticoagulant therapy during the study (prophylactic use of low-dose aspirin is allowed);
    3. Patients with unhealed, poorly healed wounds or untreated fractures;
    4. Patients with evidence of gastrointestinal perforation, fistula, intra-abdominal abscess, and free gas in the abdominal cavity within 6 months before the first dose;
    5. Subjects with urine protein>1+ undergo 24-hour urine protein quantification, and urine protein ≥1g/24 hours;
    6. Patients with reversible posterior encephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome (RPLS).
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Rulonilimab plus cisplatin/carboplatin + paclitaxel ± bevacizumab

    Drug: Rulonilimab · Drug: cisplatin/carboplatin + paclitaxel ± bevacizumab

  • Placebo comparator
    Placebo plus cisplatin/carboplatin + paclitaxel ± bevacizumab

    Drug: Placebo · Drug: cisplatin/carboplatin + paclitaxel ± bevacizumab

Interventions

  • Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons. Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons. Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.

  • DrugPlacebo

    Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons. Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons. Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.

  • Drugcisplatin/carboplatin + paclitaxel ± bevacizumab

    cisplatin/carboplatin + paclitaxel ± bevacizumab

06

What researchers measure

Primary outcomes

  1. Objective tumor response rate (ORR) assessed by RECIST1.1

    Defined as the proportion of subjects who achieves a best overall response of CR or PR based on RECIST1.1

    Time frame: up to 2 years

  2. Progression Free Survival (PFS) assessed by RECIST1.1

    Defined as the time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first.

    Time frame: up to 2 years

  3. Overall Survival (OS)

    Defined as the time from the date of randomization to the date of death due to any Defined as the time from the date of randomization to the date of death due to any reason

    Time frame: up to 2 years

Secondary outcomes

  1. Disease Control Rate (DCR)

    Defined as the proportion of subjects' response of CR, PR, or SD based onRECIST1.1

    Time frame: up to 2 years

  2. Duration of Response (DOR)

    Defined as the time from the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first

    Time frame: up to 2 years

  3. Time to Response (TTR)

    Defined as the time from the date of randomization to the date when the response criteria are first met, based on RECIST1.1

    Time frame: up to 2 years

Other outcomes

  1. The Incidence and Severity of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with an AE or SAE

    Time frame: up to 2 years

  2. Healthy related quality of life (HRQoL)

    EORTC QLQ-C30 will be used

    Time frame: up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Sep 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 1, 2025
StartActual
Sep 26, 2024
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06755515
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Sep 26, 2024
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jan 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rulonilimab

Start the discussion